Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Your comments will be sent to our moderator for review.
By submitting your information you agree to our Privacy and Cookie Policy.

Report comment to moderator

Required fields.


New drug class for overactive bladder launched


Beta -3 receptor agonists like Mirabegron should never be used with any patients with atrial fibrillation or any other arrythmias. It would be interesting to see whether mirabegron can promote weight loss in OAB patients who are also obese because there is theoretical evidence that beta-3 agonists can act as selective metabolism stimulators. Patrick Movsessian

Posted date

4 July, 2014

Posted time

6:22 pm